MRI Interventions Exhibiting Its Advanced Neurosurgical Navigation Platform, the ClearPoint Neuro Intervention System, at AANS 2013 Annual Meeting

Presentation Highlighting Application of the ClearPoint System and Interventional Magnetic Resonance Imaging (iMRI) in Deep Brain Stimulation (DBS) Surgery to be Given During the Stereotactic & Functional Surgery Session

NEW ORLEANS, April 29, 2013 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint^® Neuro Intervention System is on exhibit at the 2013 Annual Meeting of the American Association of Neurological Surgeons (AANS) through Wednesday, May 1, 2013, in New Orleans. Conference attendees are invited to visit the MRI Interventions booth (#1221) to explore an interactive presentation detailing the ClearPoint System's unique suitability for a wide range of neurosurgical applications.

The ClearPoint System will also be featured in a presentation titled "Intraoperative MRI – ClearPoint and iMRI," to be given during the Stereotactic & Functional Surgery Section Session on Wednesday, May 1, 2013 at 2:00 p.m. CDT. Dr. Paul Larson, Associate Professor and Vice Chair of Neurological Surgery at University of California, San Francisco (UCSF) and Chief of Neurosurgery Service at Veterans Affairs Medical Center, San Francisco, will discuss his team's experiences using the ClearPoint System and iMRI to assist in the placement of DBS electrodes at UCSF Medical Center.

The ClearPoint System is a navigation platform designed to allow real-time, direct visualization during minimally-invasive neurosurgical procedures. ClearPoint software works with MRI to assist surgeons in planning a target and trajectory, and the SmartFrame^® targeting device enables the MRI-guided alignment and insertion of surgical instruments. The ClearPoint System allows surgeons to monitor the placement of instruments and devices in the brain under real-time MRI guidance and to visually confirm results of a procedure before removing a patient from the operating environment. The ClearPoint platform is being utilized to assist physicians in a variety of neurosurgical procedures, including DBS lead placement, focal laser ablation, brain biopsy, and direct drug delivery to malignant brain tumors.

About MRI Interventions

Founded in 1998, MRI Interventions (OTCQB:MRIC) is a commercial stage medical technology company creating innovative platforms for performing the next generation of minimally-invasive surgical procedures in the brain and heart. Utilizing a hospital's existing MRI suite, the company's FDA-cleared and CE-marked ClearPoint^® system is designed to enable a range of minimally-invasive procedures in the brain. MRI Interventions has a co-development and co-distribution agreement with Brainlab, a leader in software-driven medical technology, relating to the ClearPoint system. In partnership with Siemens Healthcare, MRI Interventions is developing the ClearTrace^® system to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation. Building on the imaging power of MRI, the company's interventional platforms strive to improve patient care while reducing procedure costs and times. MRI Interventions is also working with Boston Scientific Corporation to incorporate its MRI-safety technologies into Boston Scientific's implantable leads for cardiac and neurological applications. For more information, please visit www.MRIinterventions.com.

CONTACT: David Carlson
         Chief Financial Officer
         MRI Interventions, Inc.
         901-522-9300

Released April 29, 2013